Genmab A/S (NASDAQ:GMAB) Stock Gets Price Target Increase from TD Cowen

Genmab A/S (NASDAQ:GMAB) had its price target increased by analysts at TD Cowen from $43.00 to $52.00 in a research report issued on Monday, Benzinga reports. The firm presently has a “buy” rating on the stock. TD Cowen‘s price target would suggest a potential upside of 17.75% from the stock’s previous close.

Other equities research analysts have also recently issued research reports about the stock. Morgan Stanley set a $42.00 target price on shares of Genmab A/S in a research note on Tuesday, October 20th. Weiss Ratings raised shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, September 1st. JPMorgan Chase & Co. raised shares of Genmab A/S from a “neutral” rating to an “overweight” rating in a research note on Monday. Guggenheim raised their price objective on shares of Genmab A/S from $45.00 to $54.00 and gave the company a “buy” rating in a research report on Monday, October 5th. Finally, HC Wainwright lifted their target price on shares of Genmab A/S from $40.00 to $50.00 and gave the company a “buy” rating in a research note on Wednesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $44.39.

Genmab A/S Stock Performance

GMAB traded up $0.37 during midday trading on Monday, reaching $44.16. The company had a trading volume of 4,137,111 shares, compared to its average volume of 2,271,859. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81. The business has a 50-day moving average of $35.25 and a two-hundred day moving average of $30.23. The company has a market cap of $27.56 billion, a P/E ratio of 34.77, a P/E/G ratio of 2.01 and a beta of 0.81. Genmab A/S has a 1 year low of $23.62 and a 1 year high of $45.45.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.17. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%. The firm had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.12 billion. As a group, equities research analysts predict that Genmab A/S will post 1.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Several institutional investors and hedge funds have recently modified their holdings of GMAB. Personal CFO Solutions LLC lifted its position in shares of Genmab A/S by 3.7% in the 1st quarter. Personal CFO Solutions LLC now owns 10,866 shares of the company’s stock valued at $292,000 after acquiring an additional 386 shares in the last quarter. Versant Capital Management Inc lifted its position in shares of Genmab A/S by 4.5% in the third quarter. Versant Capital Management Inc now owns 12,235 shares of the company’s stock worth $436,000 after purchasing an additional 523 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Genmab A/S by 16.4% during the second quarter. GAMMA Investing LLC now owns 3,978 shares of the company’s stock worth $109,000 after purchasing an additional 561 shares during the period. Summitry LLC grew its position in Genmab A/S by 5.3% during the first quarter. Summitry LLC now owns 11,170 shares of the company’s stock valued at $300,000 after purchasing an additional 567 shares in the last quarter. Finally, AdvisorShares Investments LLC increased its stake in Genmab A/S by 2.2% in the 1st quarter. AdvisorShares Investments LLC now owns 30,853 shares of the company’s stock valued at $828,000 after buying an additional 653 shares during the period. Institutional investors own 7.07% of the company’s stock.

More Genmab A/S News

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Strong head-and-neck cancer results: Genmab reported updated Phase 2 data for petosemtamab plus pembrolizumab in first-line recurrent or metastatic PD-L1-positive head and neck cancer. The combination produced median overall survival of 28.2 months, a 63% overall response rate, median progression-free survival of 9.0 months and a 19% complete-response rate. A Phase 3 program is ongoing, with topline results expected later this year. Genmab Phase 2 head and neck cancer data
• Positive Sentiment: Additional oncology catalyst: A report said Genmab’s experimental therapy reduced the risk of death and disease progression for ovarian-cancer patients in a late-stage clinical trial, adding to optimism around the company’s clinical pipeline. Genmab shares after positive cancer study results
• Positive Sentiment: Colorectal-cancer data reinforce pipeline potential: Updated Phase 2 results for petosemtamab combined with chemotherapy showed objective response rates of 75% in first-line and 67% in second-line metastatic colorectal cancer, supporting ongoing global Phase 3 trials. Genmab colorectal cancer data
• Positive Sentiment: Analyst upgrade: JPMorgan raised Genmab from “neutral” to “overweight,” potentially improving investor confidence in the stock.
• Positive Sentiment: Bullish options activity: Traders purchased 12,591 call options, about 403% above typical call volume, indicating elevated speculative interest in further gains.

About Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.

Genmab’s marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.